Table 4.

Deterministic sensitivity analyses

Scenario	Incremental Costa	Incremental Effect	ICERa
Base case	11	0.0012	9167
Exclude “other” fractures	0	0.0014	0
Intervention costs
25% decrease	0	0.0012	0
25% increase	22	0.0012	18,440
Persistence with treatment
30%, rather than 60%	34	0.0006	56,667
Adherence with treatment
50%, rather than 80%	57b	0.0004	142,500
Bisphosphonate price
100% increase	31	0.0012	25,833
200% increase	51	0.0012	42,500
500% increase	111	0.0012	92,500
Effect of bisphosphonate 35% fracture reduction	31	0.0008	38,750
Discount rate (rather than 3%)
0% discount rate	−30	0.0020	nab
1% discount rate	−13	0.0016	nab
5% discount rate	26	0.0009	28,889
Mortality benefit (11% reduction)	12	0.0021	5714
Increased mortality 1 year post-spine fracture	11	0.0013	8462

QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio

^aCosts are expressed in constant 2014 Canadian dollars (multiply by 0.905 to convert to 2014 US dollars [28])

^bThe ICER is not applicable since the intervention dominates usual care, i.e., the intervention is less costly and more effective